Phenotypical analysis of circulating T-regulatory cells in vitiligo patients
DOI:
https://doi.org/10.26577//eb.2020.v83.i2.09Abstract
Vitiligo is an autoimmune skin disease characterized by the loss of melanocytes and development of skin depigmentation foci. The exact etiology and pathogenesis of vitiligo are not fully understood, but autoimmune processes have been strongly implicated in the development of the disease. As with other autoimmune diseases, the role of dysfunction of immunosuppressive T-regulatory (Treg) cells in Vitiligo has been actively discussed. It is assumed that reduced immunosuppressive activity and Treg cell infiltration of vitiligo-affected skin lesions play a key role in a breakdown of immune tolerance leading to the development of the disease. However, the phenotypic and functional characteristics of Treg cells in vitiligo remain poorly understood. The aim of this study was to investigate the phenotype of circulating Treg cells in vitiligo. It was found that the proportion of CD4+CD25+ Treg cells, as well as the proportion of CD4+CD25+ Treg cells expressing the immunosuppressive marker CD39 and the cell adhesion and migration marker CD44, were significantly reduced in the peripheral blood of vitiligo patients with active stage of the disease comparing to healthy volunteers. Moreover, we found a decreased proportion of Treg cells possessing CD39+ and CD44+FoxP3+ phenotypes in patients with stable vitiligo. Obtained data suggest that Treg cells play an important role in vitiligo pathogenesis and may indicate a decrease in the functional activity and the recruitment of Treg cells into vitiligo lesions leading to a lack of immunological surveillance.
Key words: T regulatory cells, vitiligo, CD39, CD44.
References
2. van den Boorn, J.G., Konijnenberg, D., Dellemijn, T.A., et al. “Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.” J. Invest. Dermatol. 129, no. 9 (2009): 2220-2232.
3. Ogg, G.S., Rod Dunbar, P., Romero, P., Chen, J.L., Cerundolo, V. “High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.” J. Exp. Med. 188, no. 6 (1998): 1203-1208.
4. Strassner, J.P., Harris, J.E. “Understanding mechanisms of autoimmunity through translational research in vitiligo.” Curr. Opin. Immunol. 43, (2016): 81-88.
5. Le Poole, I.C., van den Wijngaard, R.M., Westerhof, W., Das, P.K. “Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance.” Am. J. Pathol. 148, no. 4 (1996): 1219-1228.
6. Le Poole, I.C., Stennett, L.S., Bonish, B.K., et al. “Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin.” Br. J. Dermatol. 149, no. 4 (2003): 739–748.
7. Ujiie, H. “Regulatory T cells in autoimmune skin diseases.” Exp. Dermatol. 28, no. 6 (2019): 642-646.
8. Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M. “Regulatory T cell and immune tolerance.” Cell. 133, no. 5 (2008): 775-787.
9. Taams, L.S., Akbar, A.N. “Peripheral generation and function of CD4+CD25+ regulatory T cells.” Curr. Top. Microbiol. Immunol. 293, (2005): 115-131.
10. Ballke, C., Gran, E., Baekkevold, E.S., Jahnsen, F.L. “Characterization of Regulatory T-Cell Markers in CD4+ T Cells of the Upper Airway Mucosa.” PLoS One. 11, no. 2 (2016): e0148826.
11. Allan, S.E., Alstad, A.N., Merindol, N., et al. ”Generation of potent and stable human CD4+ T regulatory cells by activation- independent expression of FOXP3.” Mol. Ther. 16, no. 1 (2008): 194-202.
12. Nishikawa, H., Sakaguchi, S. “Regulatory T cells in tumor immunity.” Int. J. Cancer. 127, (2010): 759–767.
13. Galdino, N.A.L., Loures, F.V., Araújo, E.F., et al. “Depletion of regulatory T cells in ongoing paracoccidioidomycosis rescues protective Th1/Th17 immunity and prevents fatal disease outcome.” Sci. Rep. 8, (2018): e16544.
14. Vignali, D.A., Collison, L.W., Workman, C.J. “How regulatory T cells work.” Nat. Rev. Immunol. 8, (2008): 523-532.
15. Maeda, Y., Nishikawa, H., Sugiyama, D., et al. “Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals.” Science. 346, (2014): 1536-1540.
16. Eby, J.M., Kang, H.K., Klarquist, J., et al. “Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.” Pigment Cell Melanoma Res. 27, no. 6 (2014): 1075-1085.
17. Lili, Y., Yi, W., Ji, Y., et al. “Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo.” PLoS One. 7, (2012): e37513.
18. Ben Ahmed, M., Zaraa, I., Rekik, R., et al. “Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo.” Pigment Cell Melanoma Res. 25, (2012): 99-109.
19. Dwivedi, M., Kemp, E.H., Laddha, N.C., et al. “Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics.” Autoimmun Rev. 14, no. 1 (2015): 49-56.
20. Klarquist, J., Denman, C.J., Hernandez, C., et al. “Reduced skin homing by functional Treg in vitiligo.” Pigment Cell Melanoma Res. 23, no. 2 (2010): 276-286.
21. Dwivedi, M., Laddha, N.C., Arora, P., Marfatia, Y.S., Begum, R. “Decreased regulatory T-cells and CD4(+) /CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo.” Pigment Cell Melanoma Res. 26, (2013): 586–591.
22. Abdallah, M., Lotfi, R., Othman, W., Galal, R. “Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo.” Int. J. Dermatol. 53, (2014): 940-946.
23. Ono, S., Tanizaki, H., Otsuka, A., et al. “Coexistent skin lesions of vitiligo and psoriasis vulgaris. Immunohistochemical analyses for IL-17A-producing cells and regulatory T cells.” Acta Derm. Venereol. 94, (2014): 329-330.
24. DeGrendele, H.C., Estess, P., Picker, L.J., Siegelman, M.H. “CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte/endothelial cell primary adhesion pathway.” J. Exp. Med. 183, (1996): 1119-1130.
25. Campbell, D.J., Koch, M.A. “Phenotypical and functional specialization of FOXP3+ regulatory T cells.” Nat. Rev. Immunol. 11, no. 2 (2011): 119-130.
26. Firan, M., Dhillon, S., Estess, P., Siegelman, M.H. “Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44.” Blood. 107, no. 2 (2006): 619-627.
27. Tang, Q., Henriksen, K.J., Bi, M., et al. “In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.” J. Exp. Med. 199, (2004): 1455-1465.
28. Borsellino, G., Kleinewietfeld, M., Di Mitri, D., et al. “Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression.” Blood. 110, (2007): 1225-1232.
29. Deaglio, S., Dwyer, K.M., Gao, W., et al. “Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.” J. Exp. Med. 204, (2007): 1257-1265.
30. Shevach, E.M. “Mechanisms of FOXP3 T regulatory cell-mediated suppression.” Immunity. 30, (2009): 636–45.
